Insmed To Present at Two June Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced its management will present at two upcoming virtual investor events: the Jefferies Virtual Healthcare Conference on June 1, 2021, at 9:00 a.m. ET, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 2:10 p.m. ET. Both presentations will be webcast live and archived for 30 days. Insmed focuses on transforming the lives of patients with serious diseases and has a robust pipeline of therapies for unmet medical needs.
Details
News Market Reaction – INSM
The recorded move for INSM in the trading session of this news was -4.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor events:
- The Jefferies Virtual Healthcare Conference on June 1, 2021 at 9:00 a.m. ET in a corporate presentation
- The Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021 at 2:10 p.m. ET in a fireside chat
Each presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of each live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.
Contact:
Investors:
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-two-june-conferences-301298212.html
SOURCE Insmed Incorporated
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.